Wacker Biotech News and Resources

Wacker Biotech has entered a strategic collaboration with Expression Manufacturing to deliver fully integrated viral vector manufacturing solutions for the cell and gene therapy sector. The partnership brings together Wacker’s proprietary PLASMITEC® platform and Expression’s LentET™ viral vector technology. The agreement

Wacker Biotech has announced a strategic collaboration with RNAV8 Bio, a Boston-based company specialising in mRNA engineering. The partnership aims to accelerate the development and production of advanced mRNA-based therapeutics for the biopharma industry. The collaboration leverages Wacker Biotech’s capabilities in plasmid

MinervaX ApS, a Danish biotechnology firm, has entered a collaboration with Wacker Biotech, a contract development and manufacturing organisation (CDMO), to manufacture the active protein ingredients for its Group B Streptococcus (GBS) vaccine. MinervaX is developing a novel prophylactic vaccine